Ignite Creation Date:
2025-12-24 @ 12:35 PM
Ignite Modification Date:
2025-12-27 @ 9:29 PM
Study NCT ID:
NCT05664061
Status:
UNKNOWN
Last Update Posted:
2023-03-01
First Post:
2022-12-15
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Bioequivalence With Clinical Endpoint Study of Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 mcg Inhalation Powder/GSK in Patients With Asthma
Sponsor:
Respirent Pharmaceuticals Co Ltd.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-01-30
Start Date Type:
ACTUAL
Primary Completion Date:
2023-07-31
Primary Completion Date Type:
ESTIMATED
Completion Date:
2023-12-31
Completion Date Type:
ESTIMATED
First Submit Date:
2022-12-15
First Submit QC Date:
None
Study First Post Date:
2022-12-23
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-02-28
Last Update Post Date:
2023-03-01
Last Update Post Date Type:
ACTUAL